咪唑斯汀长疗程递减疗法治疗慢性荨麻疹的临床与实验观察  

Clinical observation of long-term decrement mizolastine therapy in the treatment of chronic urticaria

作　　者：王宏瑾[1] 张江安[2] 于建斌[2] 

机构地区：[1]郑州大学护理学院临床教研室,河南郑州450052 [2]郑州大学第一附属医院皮肤性病科,河南郑州450052

出　　处：《临床皮肤科杂志》2012年第7期440-442,共3页Journal of Clinical Dermatology

摘　　要：目的:探讨咪唑斯汀长疗程递减疗法治疗慢性荨麻疹的疗效和安全性。方法:将患者随机分为试验组和对照组,每组各50例。前者采用长疗程递减疗法(10mg,1日1次×4周→10mg,2日1次×4周→10 mg,3日1次×4周),后者采用长疗程连续疗法,即咪唑斯汀10mg,每日1次,连续12周。并检测患者治疗前后血浆组胺水平的变化。结果:试验组和对照组的有效率分别为85.11%、89.36%,二者差异无统计学意义(x^2=0.382,P=0.536);治疗后试验组和对照组的血浆组胺水平分别为(2.54±0.91)nmol/L、(2.38±1.04)nmol/L,差异也无统计学意义(t=0.795,P=0.429)。结论:咪唑斯汀长疗程递减疗法治疗慢性荨麻疹安全、有效,且方便,值得临床推广应用。Objective： To observe the efficacy and safety of long-term decrement mizolastine therapy in the treatment of chronic urticaria. Methods： One hundred patients with chronic urticaria were randomly divided into two groups, the experi- mental group and control group. The experimental group was treated with long-term decrement mizolastine therapy （10 mg ev- ery day in the first four weeks, 10 mg every other day in the next 4 weeks, 10 mg per three days in the last 4 weeks）,and the control group with long-term mizolastine therapy （10 mg every day for 12 weeks）. In addition, EIA was used to detect the plasma level of histamine in both groups before and after treatment. Results： The total effective rate of the experimental group was 85.11%, and 89.36% in the control group respectively. There was no significant difference between the two groups＇ total effective rate （ X2 = 0.382, P= 0.536）. After treatment, The plasma level of histamine was （2.54±0.91）nmol/L in the experimental group, compared to （2.38±1.04）nmol/L in the control group （t = 0.795, P= 0.429）. Conclusions： It is effective, safe and convenient for long-term decrement mizolastine therapy in the treatment of chronic urticaria.

关 键 词：荨麻疹 慢性 组胺 咪唑斯汀 疗程 

分 类 号：R442.2[医药卫生—诊断学]